Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups
Title:
Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups
Author:
Gogishvili, M. Kilickap, S. Sezer, A. Gümüş, M. Bondarenko, I. Özgüroğlu, M. He, X. Gullo, G. Rietschel, P. Quek, R.G.W.